Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Mantle-Cell × Thalidomide × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Medulloblastoma 1 Lymphoma, Mantle-Cell 1 Liver Neoplasms 1 Ependymoma 1 Carcinoma, Hepatocellular 1

Interventions

Rituximab 19 Cyclophosphamide 15 fludarabine 9 acalabrutinib 9 venetoclax 8 ibrutinib 8 zanubrutinib 7 pirtobrutinib 7 Magnetic Resonance Spectroscopy 7 CT-P10 7 obinutuzumab 6 glofitamab 6 fludarabine phosphate 6 Cytarabine 6 Specimen Handling 5 Lenalidomide 5 Bendamustine Hydrochloride 5 Vincristine 4 Doxorubicin 4 Biopsy 4 Whole-Body Irradiation 3 Prednisone 3 Mycophenolic Acid 3 Immunotherapy, Adoptive 3 Etoposide 3 Dexamethasone 3 Cyclosporine 3 brexucabtagene autoleucel 2 Therapeutics 2 Tacrolimus 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02858804 2026-02-11

BDH-MCL01

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Completed

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡